Stem Cell Mobilization With Plerixafor in Diabetic vs Control Subjects
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess whether there are differences in the mobilization of
CD34+ cells and EPC in response to Mozobil in patients with diabetes mellitus compared to
subjects without diabetes. Currently, there are no non-invasive methods for the study of bone
marrow function in humans. This project aims to evaluate in patients with type 1 or type 2
diabetes mellitus the ability to mobilize CD34+ cells and EPC from the bone marrow to the
periphery in response to the exogenous mobilizing agent AMD3100 / plerixafor (Mozobil),
compared with a group of non-diabetic individuals. While it has been recently shown that
diabetic patients do not respond to mobilization induced by G-CSF (Filgrastim), the
investigators herein hypothesize that diabetic patients can adequately respond to
mobilization induced by Plerixafor